CommonSense
Noninvasive Diagnostic Kits for Womens Health
Company Overview
Snapshot
Founded in June 1999, CommonSense operated with 51–200 employees, developing noninvasive diagnostic kits. The company was acquired by PEPTONIC Medical AB in October 2021.
Business overview
CommonSense specializes in creating noninvasive diagnostic kits for women's health. Their core technology involves built-in sensing capabilities to accurately monitor vaginal and urinary tract health. The company's easy-to-use, color-coded products, such as AL-SENSE and VS-SENSE, determine pH levels to indicate health status or provide early warnings for conditions like amniotic fluid leakage or infections. CommonSense serves the healthcare industry, including clinics and hospitals, and directly targets consumers, particularly women, operating within the Health Tech & Life Sciences sector, with a focus on Medical Devices and Diagnostics Devices.
Strategic signal
In October 2021, CommonSense was acquired by PEPTONIC Medical AB. This acquisition signals a strategic consolidation within the women's health diagnostics market, indicating a potential expansion of PEPTONIC Medical AB's product portfolio and market reach with CommonSense's noninvasive diagnostic technologies.
Company Intelligence Q&A
- What is CommonSense's primary focus?
- CommonSense focuses on providing noninvasive diagnostic kits for women's health, utilizing built-in sensing capabilities to monitor vaginal and urinary tract health.
- When was CommonSense founded?
- CommonSense was founded in June 1999.
- What is AL-SENSE?
- AL-SENSE is a panty liner product from CommonSense designed as a self-test for pregnant women to detect possible leakage of amniotic fluid, distinguishing it from urine.
- What is VS-SENSE?
- VS-SENSE is a swab equipped with an acidity indicator that enables diagnostic differentiation between a possible fungal infection and a bacterial or Trichomoniasis infection.
- What was a significant corporate event for CommonSense?
- In October 2021, CommonSense was acquired by PEPTONIC Medical AB for $375,000, as approved by the court.